Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.37 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.36 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14191347 | 1.00 | GABRR1 (0.42) | GABRR1SLC1A2SLC1A1GABRR2HPSE | |
| SCHEMBL22602662 | 1.00 | GABRR1 (0.42) | GABRR1SLC1A2SLC1A1GABRR2HPSE | |
| Water SCHEMBL31468829 | 0.97 | GABRR1 (0.40) | GABRR1SLC1A2SLC1A1GABRR2HPSE | |
| SCHEMBL25347129 | 0.92 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL3227345 | 0.92 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL16380722 | 0.81 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL163825 | 0.81 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL30756696 | 0.81 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL18253254 | 0.81 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 | |
| SCHEMBL17484815 | 0.81 | GABRR1 (0.43) | GABRR1SLC1A2SLC1A1GABRR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4380633-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | Rayzebio, Inc. (US) | 2024-06-12 | — | — | EP | claimed |
| WO-2023191839-A9 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2023191839-A2 | STABILIZED COMPOSITIONS OF RADIONUCLIDES AND USES THEREOF | RAYZEBIO, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| EP-4583979-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| CN-119997982-A | Antibody drug conjugates comprising NMT inhibitors and uses thereof | 迈里克斯制药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119968369-A | Cytotoxic imidazo [1,2-a ] pyridine compounds and their use in therapy | 迈里克斯制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2024052685-A1 | CYTOTOXIC IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AND THEIR USE IN THERAPY | MyricX Pharma Limited (GB) | 2024-03-14 | — | — | WO | disclosed |
| EP-3658109-A1 | COOLING AND FLAVOR BOOSTING COMPOSITIONS | Firmenich SA (CH) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019070906-A1 | PROBE FOR SELECTIVELY CHARACTERIZING ENZYMES INVOLVED IN XENOBIOTIC METABOLISM AND METHOD OF MAKING AND USING THE SAME | WRIGHT AARON T (US) | 2019-04-11 | — | — | WO | disclosed |
| US-20180002275-A1 | HYPDH INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF KIDNEY STONES | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2018-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002275-A1 | HYPDH INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF KIDNEY STONES | XDH, GLS, GRHPR | GABRR1 1840/4885SLC1A2 1748/4885SLC1A1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.